And One Step Back
And One Step Back
Source: Lange DJ, et al. Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol 1998;55:93-96.
Antioxidants have been proposed to be of potential benefit in ALS, particularly since the discovery of the superoxide dismutase mutation in the familial variant (Nature 1993;362:59-62). Sadly, of 133 patients with ALS randomized to receive selegiline (Eldepryl), a monoamine oxidase-B inhibitor with antioxidant properties, 5 mg po bid, or placebo for six months, no significant benefit appeared in the treatment group with respect to rate of disease progression, as measured by the Appel ALS score, or in survival. -mr
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.